Agilent Gets CE-IVD Mark for Cancer Diagnostic Test

Agilent Technologies has earned a CE-IVD mark for its PD-L1 IHC 28-8 pharmDx diagnostic test to guide first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.

The immunohistochemical test looks for the PD-L1 biomarker that is critical for response to anti-PD-1 therapies such as Bristol Meyers Squibb’s immunotherapeutic drug Opdivo (nivolumab).

When used together with the test, treatment with Opdivo in combination with chemotherapy shows superior overall survival and progression-free survival compared to chemotherapy alone, the company said.